Abstract preparation and submission guidelines

General

It is advisable to begin submitting your abstract only when its content is final. After **Tuesday, May 30, 2017**, authors cannot change abstract content. Should changes be necessary before this date, the Symposium Secretariat will advise you on how changes could be implemented.

Language

Abstracts should be written in English language in a generally accessible style.

Title

Each abstract should have a brief descriptive title of no more than 140 characters, including spaces. The title should be written in sentence case. Trademarks are not allowed in the abstract title.

Authors

A maximum of 20 authors per abstract is allowed. Names, institutional affiliations, cities, and countries of all contributing authors should be provided.

The person submitting the abstract will be considered the submitting author, and his/her name will automatically appear on the abstract.

During submission (under the heading "Applicant Type"), the order in which authors' names should appear on the abstract must be provided, as well as the identity of the presenting author. Any one of the authors may be identified as the presenting author.

Authors' and institutes' names will appear on the abstract exactly as entered by the submitting author.

All communication regarding an abstract will be sent to the submitting author, irrespective of the designation of the presenting author.

Text

The abstract text should have a minimum of 300 characters and should not exceed 2300 characters, including spaces. If an illustration (simple photograph/table/figure) is uploaded for inclusion in the abstract, the maximum allowable character count is 1800 (including spaces). If the character count is not reduced adequately, the symposium organizers reserve the right to omit the illustration from the abstract. It is suggested, but not mandatory, to organize abstracts in sections as follows: Background (or: Introduction); Materials and methods; Results; Conclusions.

The identity of technologies (approved or experimental) mentioned in the title or abstract text should be disclosed in the abstract text or by means of a reference to a publicly accessible source.

Trademarks may be included in the abstract text between brackets, but only the first time the product/service/technology is mentioned.

Authors are advised that abstracts without an explicit concluding sentence stating the significance of the findings is not permissible. It is not satisfactory to say that the results will be discussed.

Illustration

One simple figure/table/photograph may be added to an abstract. Make reference to the illustration in the abstract text and provide a brief caption.

References & acknowledgements

A maximum of five abbreviated literature references may be added at the end of the abstract text. State only the first author's name and bibliography (not paper titles) of each reference. Mention relevant sources of funding of the work described in this section. References and acknowledgements are included in the total character count for the abstract text.

Abstract topic

When asked to identify the abstract topic during submission (under the heading "Submission Group" on the submission web page), select the best matching topic for your abstract. If none of the pre-specified topics applies to your abstract, select "Other topics". The topic "Invited lectures" should not be selected for submitted abstracts.

Keywords

Provide at least two specific keywords, describing the content of your abstract for scheduling and indexing purposes. Good keywords are: drug name(s), drug code number(s), drug target, drug class, biomarker or diagnostic name, tumor type, type of study (e.g. phase 1), et cetera. Avoid general terms such as cancer, cell line, personalized therapy, patient, et cetera.

Submission

Once you have completed all mandatory fields, you may submit your abstract or save it without actually submitting it such that you may return to your abstract to complete and submit it at a later time. However, late abstracts submitted after the submission deadline of May 30, 2017 will not be considered for poster presentation at the symposium.
After submission, you cannot change abstract content. Should changes be necessary after submission, the WIN 2017 Secretariat will advise you on how changes could be implemented. Please, note that changes cannot be implemented after May 30, 2017 and that abstracts cannot be withdrawn after this date.

Copyrights, editing and publication
Submission of an abstract implies the exclusive, unrestricted granting of copyrights on the abstract to the WIN 2017 symposium organizer and its partners/publishers.
The WIN 2017 symposium organizers reserve the right to edit abstracts for obvious spelling or grammatical errors before publication without the authors' consent.

Encore abstracts
Abstracts presented at previous symposiums (encore abstracts) are potentially acceptable, but scheduling for presentation cannot be guaranteed. All submitted abstracts will undergo peer review

by independent experts and their ratings will determine abstract scheduling. Acceptability of encore abstracts depends on various factors. For instance, if it provides supporting data for an invited lecture it might be acceptable for poster presentation. Acceptability of an abstract of a clinical study that was presented elsewhere, will increase if updated results are reported in the abstract.

Important dates

Tuesday, May 30, 2017

Deadline abstract submission, withdrawal and change of abstract content.

Abstracts entered but not submitted by this date will be discarded.

Friday, June 9, 2017

Notification of abstract scheduling/rejection to submitting author

Wednesday, June 14, 2017

Deadline registration for presenting authors

Necessary to ensure abstract scheduling